News
Pembrolizumab improves event-free survival in early TNBC
Neoadjuvant pembrolizumab benefits early TNBC patients regardless of disease stage and nodal status. Event-free survival improved by about 35%...
News
ASH studies look at racial disparities in ALL care, outcomes
Findings of two studies on U.S. blood cancer care suggest that “structural racism” may play a role in worse outcomes among young Hispanic and...
News
NHL: As a second-line treatment in phase 3 trial, tisa-cel disappoints
In this phase 3 BELINDA study, CAR T-cell therapy did not prolong event-free survival as a second-line treatment of aggressive non-Hodgkin...
News
Are newer migraine therapies better? It depends
“Triptans will be around for a long time, but the newer medications are here to stay,”
News
Delays in cancer referral, diagnosis linked with morbidities
Patients with multiple morbidities were much more likely to have their cancer diagnosed at least 60 days after initial primary care consultation...
News
TKI/BiTE combo extends survival of older patients with Ph+ALL
In these elderly patients who are not candidates for chemo, the issue is whether we can prolong remission by the addition of other treatments,...
Article
Clinical Progress Note: Rhythm Control for Patients With Atrial Fibrillation
1University of Colorado Anschutz Medical Center, Department of Medicine, Aurora, Colorado; 2University...